QuidelOrtho Corporation (QDEL)
QuidelOrtho: Too Much Uncertainty Around Earnings Keeping Short-Interest Elevated
QuidelOrtho Corporation continues its steep decline, with over 40% losses since February and a $5B market cap drop since its 2022 merger. QDEL's Q4 and Q1 results both disappointed, with 2026 EPS guidance cut twice in three months and consensus now at $1.85 per share. Profitability struggles are compounded by rising debt, high inventory, weak Chinese sales, and a soft respiratory season, with no clear mitigation strategies outlined.
QuidelOrtho (QDEL) Moves 32.2% Higher: Will This Strength Last?
QuidelOrtho (QDEL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
QDEL's strong portfolio, cost-saving progress and mixed first-quarter results support growth, though respiratory reliance remains a risk.
Is the Options Market Predicting a Spike in QuidelOrtho Stock?
Investors need to pay close attention to QDEL stock based on the movements in the options market lately.
QDEL Stock Down as Q1 Earnings Miss Estimates, Revenues Down Y/Y
QuidelOrtho posts a wider Q1 loss as revenues fell 10.5% year over year, with weakness in respiratory testing pressuring margins and cash flow.
QuidelOrtho Corporation (QDEL) Q1 2026 Earnings Call Transcript
QuidelOrtho Corporation (QDEL) Q1 2026 Earnings Call Transcript
QuidelOrtho (QDEL) Reports Q1 Loss, Tops Revenue Estimates
QuidelOrtho (QDEL) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of $0.37. This compares to earnings of $0.74 per share a year ago.
Earnings Preview: QuidelOrtho (QDEL) Q1 Earnings Expected to Decline
QuidelOrtho (QDEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
QuidelOrtho Looks Mispriced If 2026's FCF Turnaround Materializes
QuidelOrtho's (QDEL) reported weakness is concentrated in post-COVID Point of Care and the deliberate US donor-screening exit. However, the rest of their portfolio is actually growing. Labs is the primary revenue engine, contributing 55% of sales in 2025. Likewise, Immunohematology also expanded and supports a healthier underlying mix.
Why Is QuidelOrtho (QDEL) Down 24.5% Since Last Earnings Report?
QuidelOrtho (QDEL) reported earnings 30 days ago. What's next for the stock?
QDEL Expands Immunoassay Portfolio Via Lifotronic Supply Agreement
QuidelOrtho inks Lifotronic supply deal, adding 70+ assays and new analyzer platforms to boost global immunoassay reach and recurring revenue potential.
QuidelOrtho Q4 Earnings and Revenues Beat Estimates, Margins Down
QDEL beats Q4 estimates as Labs and global growth lift sales, but shrinking margins and respiratory weakness weigh on profits.
